We are at your service for your questions and feedback.

CEO & FounderDr Paul Hammer

As its founder and CEO, Dr Paul Hammer is the visionary behind BIOMES. He received his doctorate in systems biology and bioinformatics from the Faculty of Natural Sciences at the University of Potsdam in 2012. His mission is to transfer technology from innovative and precise medical applications over to the healthcare market with the goal of improving the health and well-being of individuals. To do this, he combines DNA high-throughput technologies with machine learning algorithms to process large data records.

After his interdisciplinary scientific training and various projects at renowned institutes, such as the Max Planck Institute for Molecular Genetics in Berlin, he began his entrepreneurial career in 2010 as founder and managing director. He founded BIOMES NGS GmbH in 2017. This biotechnology company analyses the DNA of the microbes that live in and on the human body using the so-called Next-Generation Sequencing method. The result is personal microbiota profiles, on the basis of which customers receive tailored recommendations for improving their quality of life.

Professional experience

2017Founder and CEO of BIOMES NGS GmbH
2016Co-founder of Halotek UG
2010 – 2014Chief Business Officer and Research Director for Genomic Diagnostics
in the ibiomics Group
2013Head scientist of the diagnostic bioinformatics research group as a post-doc at the Technical University of Applied Sciences Wildau

Publications

A roadmap for the generation of benchmarking resources for antimicrobial resistance detection using next generation sequencing.
Petrillo M, Fabbri M, Querci M, Van den Eede G, Alm E, Aytan-Aktug D, Capella-Gutierrez S, Carrillo C, Cestaro A, Chan KG, Coque T, Endrullat C, Gut I, Hammer P, Kay GL, Madec JY, Mather AE, McHardy AC, Naas T, Paracchini V, Peter S, Pightling A, Raffael B, Rossen J, Ruppé E, Schlaberg R, Vanneste K, Weber LM, Westh H, Angers-Loustau A; 2021, F1000Research, doi: 10.12688/f1000research.39214.1

The challenges of designing a benchmark strategy for bioinformatics pipelines in the identification of antimicrobial resistance determinants using next generation sequencing technologies.
Angers-Loustau A, Petrillo M, Bengtsson-Palme J, Berendonk T, Blais B, Chan KG, Coque TM, Hammer P, Heß S, Kagkli DM, Krumbiegel C, Lanza VF, Madec JY, Naas T, O‘Grady J, Paracchini V, Rossen JWA, Ruppé E, Vamathevan J, Venturi V, Van den Eede G; 2018, F1000Research, doi: 10.12688/f1000research.14509.2

Diet Type, Antibiotic Intake and Gut Microbiota: A Lesson from a Large Cross-Sectional Study.
Philipp Franke, Carsten Krumbiegel, Benjamin Girke, Paul Hammer, Marcus Frohme, Tewodros Debebe; 2019, Archive of the International Society of Microbiota

THE INTESTINAL COMPASS – Everything you need to know about the underestimated intestine.
Paul Hammer; 2020, Publisher FORUM VIA SANITAS, ISBN: 978-3-200-06876-6

mRNA-seq with agnostic splice site discovery for nervous system transcriptomics tested in chronic pain.
Hammer, P., Banck, M.S., Amberg, R., Wang, C., Petznick, G., Luo, S., Khrebtukova, I., Schroth, G.P., Beyerlein, P., and Beutler, A.S. (2010).. Genome Research, 20, 847–860.

Alternative splicing and extensive RNA editing of human TPH2 transcripts.
Grohmann, M., Hammer, P., Walther, M., Paulmann, N., Büttner, A., Eisenmenger, W., Baghai, T.C., Schüle, C., Rupprecht, R., Bader, M., et al. (2010).. PLoS ONE, 5, e8956.

On the mutual information between interaction perplexity and function of proteins
Tscherneck, S., Strunk, S., Schmidt, C., Hammer, P., Amberg, R., Chong Wang, Gillert, R., Krause, A., Petznick, G., and Beyerlein, P. (2009), IEEE GENSIPS, pp. 1–4.

Allosteric interaction of rapid delayed rectifier protein and its role in cardiac repolarization.
Wang, C., Beyerlein, P., Hammer, P., Krause, A., Nugent, C., and Dubitzky, W. (2008). IEEE Computers in Cardiology, pp. 589–592.

Our Partners:
EFRE Logo